Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer — IPSO  

In Vitro Fertilization (IVF) Clinical Trial

Official title: IPSO Trial - Impact of Parental Support on Pregnancy Outcomes: A Multi-Center, Randomized, Open-Label Study to Evaluate the Implantation and Pregnancy Rates Following 24 Chromosome Aneuploidy Screening With Parental Support in Patients Undergoing In Vitro Fertilization (IVF)

Status Terminated

Clinical Trial Summary

Natera is recruiting patients for a research study evaluating pregnancy and implantation rates in women undergoing In Vitro Fertilization (IVF) and Preimplantation Genetic Screening (PGS). PGS is also referred to as Preimplantation Genetic Diagnosis (PGD) for aneuploidy.

Healthy women undergoing IVF who are between the ages of 35 to 42 years are being recruited to participate in a randomized study.

The purpose of this study is to determine whether PGS- testing of embryos created during IVF for chromosomal abnormalities, prior to transfer to the uterus- improves pregnancy and implantation rates in patients when compared to patients whose embryos are not tested. PGS will be conducted using 24 Chromosome Aneuploidy Screening with Parental Support from Natera.

All subjects who qualify and enroll will receive discounted IVF medications (both TEST and CONTROL arms). If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS.

Clinical Trial Description

If you meet the criteria below, you may be a candidate for this study. To participate in the study you must:

• Be a healthy, pre-menopausal female, 35-42 years of age

• Have a history of less than 3 consecutive miscarriages and no more than one failed IVF cycle

• Agree to use Ferring Pharmaceutical products during stimulation

• Agree to be randomly assigned to either the arm of the study receiving PGS (TEST arm)or the arm receiving no additional testing (CONTROL arm)

Additional screening will be conducted to determine if you are eligible to enroll.

All subjects who qualify and enroll will receive discounted IVF medications. If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

• In Vitro Fertilization (IVF)
• Preimplantation Genetic Diagnosis (PGD)
• Preimplantation Gentic Screening (PGS)

• NCT number: NCT01194531
• Study type: Interventional
• Source: Natera, Inc.
• Status: Terminated
• Phase: Phase 4
• Start date: September 2010
• Completion date: April 2013